Assessing health economic outcome in Alzheimer's disease clinical trials

Journal of Nutrition, Health and Aging

Volumn 11, Issue 4, 2007, Pages 353-356

  Jonsson L ^a  

^a European Health Economics   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL; MEMANTINE;

ALZHEIMER DISEASE; CLINICAL RESEARCH; CLINICAL TRIAL; CONFERENCE PAPER; ECONOMIC ASPECT; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR;

EID: 34547169093     PISSN: 12797707     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (36)

1. Anell, A. and U. Persson, Reimbursement and clinical guidance for pharmaceuticals in Sweden: do health-economic evaluations support decision making? Eur J Health Econ, 2005. 6(3): p. 274-9.
2. Buxton, M.J., Economic evaluation and decision making in the UK. Pharmacoeconomics, 2006. 24(11): p. 1133-42.
3. Porzsolt, F., M. Ackermann, and V. Amelung, The value of health care - a matter of discussion in Germany. BMC Health Serv Res, 2007. 7: p. 1.
4. Bergmann, J.F., [The transparency commission: evaluation and re-evaluation]. Presse Med, 2001. 30(19): p. 941-6.
5. Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease. NICE technology appraisal guidance 111. 2006, NICE - National Institute of Clinical Excellence . London.
6. Drummond, M., et al., Methods for the economic evaluation of health care programmes. Second edition ed. 1997, Oxford, England: Oxford University Press.
7. Feldman, H., et al., A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology, 2001. 57(4): p. 613-20.
8. Wimo, A., et al., An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1-year, double-blind, randomized trial. Dement Geriatr Cogn Disord, 2003. 15(1): p. 44-54.
9. Wimo, A., et al., Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease. Pharmacoeconomics, 2003. 21(5): p. 327-40.
10. Ramsey, S., et al., Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. Value Health, 2005. 8(5): p. 521-33.
11. Coyle, D. and K.M. Lee, The problem of protocol driven costs in pharmacoeconomic analysis. Pharmacoeconomics, 1998. 14(4): p. 357-63.
12. Koopmanschap, M.A., K.C. Touw, and F.F. Rutten, Analysis of costs and cost-effectiveness in multinational trials. Health Policy, 2001. 58(2): p. 175-86.
13. Coyle, D. and M.F. Drummond, Analyzing differences in the costs of treatment across centers within economic evaluations. Int J Technol Assess Health Care, 2001. 17(2): p. 155-63.
14. Claxton, K. and J. Posnett, An economic approach to clinical trial design and research priority-setting. Health Econ, 1996. 5(6): p. 513-24.
15. Briggs, A.H. and A.M. Gray, Power and sample size calculations for stochastic cost-effectiveness analysis. Med Decis Making, 1998. 18(2 Suppl): p. S81-92.
16. Caro, J.J., et al., Assessment of health economics in Alzheimer's disease (AHEAD) based on need for full-time care. Neurology, 2001. 57(6): p. 964-71.
17. Jones, R.W., P. McCrone, and C. Guilhaume, Cost effectiveness of memantine in Alzheimer's disease: an analysis based on a probabilistic Markov model from a UK perspective. Drugs Aging, 2004. 21(9): p. 607-20.
18. Jönsson, L., et al., The Cost-Effectiveness of Donepezil Therapy in Swedish Patients with Alzheimer's Disease: A Markov Model. Clinical Therapeutics, 1999. 21(7): p. 1230-40.
19. Stewart, A., R. Phillips, and G. Dempsey, Pharmacotherapy for people with Alzheimer's Disease: a Markov-cycle evaluation of five years therapy using donepezil. Int J. Geriatr. Psychiat., 1998. 13: p. 445-53.
20. Ernst, R.L., et al., Cognitive function and the costs of Alzheimer disease. An exploratory study. Arch Neurol, 1997. 54(6): p. 687-93.
21. Hux, M.J., et al., Relation between severity of Alzheimer's disease and costs of caring. Cmaj, 1998. 159(5): p. 457-65.
22. Jönsson, L., et al., Determinants of costs of care for patients with Alzheimer's disease. Int J Geriatr Psychiatry, 2006. 21(5): p. 449-59.
23. Kavanagh, S. and M. Knapp, Costs and cognitive disability: modelling the underlying associations. Br J Psychiatry, 2002. 180: p. 120-5.
24. Kronborg Andersen, C., et al., The cost of dementia in Denmark: the Odense Study. Dement Geriatr Cogn Disord, 1999. 10(4): p. 295-304.
25. Wimo, A., et al., Evaluation of the resource utilization and caregiver time in Anti-dementia drug trials - a quantitative battery, in The Health Economis of dementia, A. Wimo, et al., Editors. 1998, John Wiley & Sons: London. p. 465-499.
26. Wimo, A., et al., Resource Utilization and Cost Analysis of Memantine in Patients with Moderate to Severe Alzheimer's Disease. Pharmacoeconomics, 2003. 21(5): p. 327-340.
27. Wimo, A. and B. Winblad, Resource utilisation in dementia: RUD Lite. Brain Aging, 2003. 3: p. 48-59.
28. Wimo, A. and G. Nordberg, Validity and reliability of assessments of time Comparisons of direct observations and estimates of time by the use of the resource utilization in dementia (RUD)-instrument. Arch Gerontol Geriatr, 2006.
29. Neumann, P.J., et al., A comparison of HUI2 and HUI3 utility scores in Alzheimer's disease. Med Decis Making, 2000. 20(4): p. 413-22.
30. Neumann, P.J., et al., Health utilities in Alzheimer's disease: a cross-sectional study of patients and caregivers. Med Care, 1999. 37(1): p. 27-32.
31. Jönsson, L., et al., Patient- and proxy-reported utility in Alzheimer disease using the EuroQoL. Alzheimer Dis Assoc Disord, 2006. 20(1): p. 49-55.
32. Naglie, G., et al., Utility-based Quality of Life measures in Alzheimer's disease. Qual Life Res, 2006. 15(4): p. 631-43.
33. Dixon, S., M. Walker, and S. Salek, Incorporating carer effects into economic evaluation. Pharmacoeconomics, 2006. 24(1): p. 43-53.
34. Claxton, K., The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. J Health Econ, 1999. 18(3): p. 341-64.
35. Briggs, A.H., B.J. O'Brien, and G. Blackhouse, Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies. Annu Rev Public Health, 2002. 23: p. 377-401.
36. Doshi, J.A., H.A. Glick, and D. Polsky, Analyses of cost data in economic evaluations conducted alongside randomized controlled trials. Value Health, 2006. 9(5): p. 334-40.